Angiotensin Receptor Blockers:
Comment:
Concurrent use of renin inhibitors and angiotensin receptor blockers (ARBs) may lead to additive hyperkalemic and hypotensive effects, especially in the presence of one or more predisposing factors such as significant renal impairment, severe diabetes, potassium supplements, high potassium diet, and advanced age. Other drugs that may exhibit hyperkalemic activity include ACE inhibitors, drospirenone (Yasmin), heparins, nonselective beta-blockers, NSAIDs, COX-2 inhibitors, cyclosporine, tacrolimus, succinylcholine, pentamidine, trimethoprim, and potassium-containing salt substitutes. The product information states that aliskiren is contraindicated in patients with diabetes who are receiving ARBs.
Class 3: Assess Risk & Take Action if Necessary